Abbott ABT Medical Devices — R&D
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Abbott's medical devices — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Abbott's medical devices — R&D?
- Abbott (ABT) reported medical devices — R&D of $444M in Q1 2026.
- How has Abbott's medical devices — R&D changed year-over-year?
- Abbott's medical devices — R&D increased by 10.7% year-over-year, from $401M to $444M.
- What is the long-term trend for Abbott's medical devices — R&D?
- Over 3 years (2022 to 2025), Abbott's medical devices — R&D has grown at a 9.7% compound annual growth rate (CAGR), from $1.33B to $1.75B.
- What does medical devices — R&D mean?
- The total spending on developing new products and improving existing technologies.
- How do you interpret medical devices — R&D?
- Higher spending indicates a commitment to long-term innovation, though it must be balanced against current profitability requirements.
- How does medical devices — R&D compare across companies?
- Standard R&D expense metric for technology and healthcare companies.